Oxytrol For Women Gets OTC Green Light As Rare First-In-Class Switch
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved Merck’s overactive bladder drug Oxytrol for Women for OTC use, despite concerns raised by the Nonprescription Drug Advisory Committee in November. The company plans a launch in the fall.
You may also be interested in...
Reinventing OTCs: FDA Seeks New Models; Stakeholders Urge Renewed Focus
FDA convened a two-day hearing to solicit new ideas to replace the OTC drug monograph system as part of a broader look at ways to enhance the regulatory model for OTCs. However, the architects of the process strongly urged FDA not to overhaul the system – but instead focus more attention on it. At stake is whether FDA makes an all out push to increase OTC switches in coming years.
Reinventing OTCs: FDA Seeks New Models; Stakeholders Urge Renewed Focus
FDA convened a two-day hearing to solicit new ideas to replace the OTC drug monograph system as part of a broader look at ways to enhance the regulatory model for OTCs. However, the architects of the process strongly urged FDA not to overhaul the system – but instead focus more attention on it. At stake is whether FDA makes an all out push to increase OTC switches in coming years.
In With The Old? 2013 To Mark Rebirth Of CDER’s Pharmacy Compounding, Medical Imaging AdComms
FDA has signaled that it will re-form its Pharmacy Compounding Drugs Advisory Committee, which was dissolved in 2002, as it deals with an ongoing meningitis outbreak related to compounded steroid injections. 2012 proved to be another busy year for the Oncologic Drugs Advisory Committee, but the full drug safety/risk management panel saw a significantly lighter workload than in recent years.